Allergan Comes To Q3 Call With Deal News, But Nothing On Pfizer
This article was originally published in The Pink Sheet Daily
Executive Summary
Allergan announced a licensing deal with Mimetogen to commercialize a TrkA agonist for the treatment of dry eye disease, coinciding with its third quarter earnings call and R&D day, but avoided discussion of the elephant in the room.
You may also be interested in...
Allergan Moves Into Busy CGRP Class By Buying Merck’s Oral Drugs
Allergan agreed to pay $250 million up front for global rights two investigational oral CGRP antagonists in early clinical development for acute treatment and prevention of migraine. Several rivals are racing to develop injectable CGRP antibodies.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.